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NBEAL1 controls SREBP2 
processing and cholesterol 
metabolism and is a susceptibility 
locus for coronary artery disease
Christian Bindesbøll1*, Aleksander Aas1, Margret Helga ogmundsdottir2, Serhiy pankiv1, 
Trine Reine3,4, Roberto Zoncu  5 & Anne Simonsen  1*
Dysregulated cholesterol homeostasis promotes the pathology of atherosclerosis, myocardial 
infarction and strokes. Cellular cholesterol is mainly regulated at the transcriptional level by SREBP2, 
but also through uptake of extracellular cholesterol from low density lipoproteins (LDL) via expression 
of LDL receptors (LDLR) at the cell surface. Identification of the mechanisms involved in regulation of 
these processes are thus key to understand the pathology of coronary artery disease. Here, we identify 
the large and poorly characterized BEACH domain protein Neurobeachin-like (NBEAL) 1 as a Golgi- 
associated protein required for regulation of cholesterol metabolism. NBEAL1 is most abundantly 
expressed in arteries. Genetic variants in NBEAL1 are associated with decreased expression of NBEAL1 
in arteries and increased risk of coronary artery disease in humans. We show that NBEAL1 regulates 
cholesterol metabolism by modulating LDLR expression in a mechanism involving interaction with 
SCAP and PAQR3 and subsequent SREBP2-processing. Thus, low expression of NBEAL1 may lead to 
increased risk of coronary artery disease by downregulation of LDLR levels.
NBEAL1 belongs to a family of proteins that shares a highly conserved domain known as the BEACH (Beige 
and Chediak-Higashi) domain, found in nine human proteins. The cellular functions of most BEACH proteins 
still remain poorly defined more than a decade after the crystal structure of the BEACH domain was resolved1,2, 
but several family members are linked to membrane trafficking and/or modeling processes, including regula-
tion of lysosome size, autophagy, apoptosis and granule size3–6. Variants in genes encoding distinct BEACH pro-
teins cause several human diseases, including grey platelet syndrome (NBEAL2)7–9, Chédiak-Higashi Syndrome 
(LYST)10 and human primary microcephaly (ALFY/WDFY3)11. NBEAL1 is one of the least understood BEACH 
proteins and we therefore aimed to elucidate its cellular localization and function, as well as a potential link to 
disease.
Results and Discussion
The NBEAL1 locus has previously been associated with coronary artery disease (CAD) (also called coronary heart 
disease or coronary atherosclerosis)12,13. However, the culprit at the locus in relation to CAD has remained some-
what unclear. In order to characterize a possible role of NBEAL1 in the disease, we utilized data from the CAD 
Genome-wide Replication and Meta-analysis (CARDIoGRAMplusC4D) consortium that holds information on 
genome wide association data for CAD comprising 60,801 cases and 123,504 controls14,15. NBEAL1 is located 
on chromosome 2 and using this data we performed a lookup of variants on this chromosome that associated 
with CAD (Supplemental Table 1). Interestingly, this revealed the strongest association within chromosome 2 
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of an intron variant in NBEAL1 with 1.15-fold increased risk of CAD in carriers, present in 13% of Europeans 
(rs115654617, OR 1.15, MAF 13%; p = 3.12 × 10−18). This variant is among 291 variants that all associate with 
CAD (p < 1 × 10−8) within a 1.2 Mb distance from NBEAL1 (Fig. 1, Supplemental Table 1). We assessed whether 
these variants are inherited together more often than random by estimating their linkage disequilibrium (LD) 
and found that of these 291 variants, 207 are in LD with the NBEAL1 variant rs115654617 (r2 > 0.8; Fig. 1, 
Supplemental Table 2). Among the linked variants is a previously reported variant associated with increased 
risk of early onset myocardial infarction, (WDR12, rs6725887)12, and a previously reported variant associated 
with white matter hyperintensity volumes in stroke patients (NBEAL1, rs72934505)13. Moreover, a recent study 
connected a variant in NBEAL1 with increased atherosclerotic lesions in young persons, but this did not reach 
genome-wide significance16. Gene expression of NBEAL1 has also been reported to increase in the brain of 
patients with glioma compared to healthy controls17, and NBEAL1 was recently identified as a candidate risk gene 
for hereditary breast cancer18.
The prevalence and importance of disease-related genetic variants in non-protein-coding regions of the 
genome is well documented19,20. These variants may regulate how and when a gene is expressed20. Interestingly, 
analysis of RNA sequencing data from different human tissues held by the GTEx Portal database revealed highest 
expression of NBEAL1 in arteries (Supplemental Fig. 1a)21. According to the Ensembl database and GTEx RNA 
sequencing, three protein coding isoforms of NBEAL1 exist, where the longest isoform (ENST00000449802) 
showed highest expression in all tissues, including arteries (Supplemental Fig. 1b,c). Utilizing the GTEx Portal 
database, we analyzed a possible association of NBEAL1 rs115654617 with altered gene expression in various 
tissues. Interestingly, the variant associates strongly with decreased expression of NBEAL1 in arteries, but also 
in adipose tissue, nerve, lung and skin (Supplemental Fig. 2). Moreover, the NBEAL1 variant also associates 
with altered expression of nearby genes (ICA1L, CARF, FAM117B) in various tissues (Supplemental Table 3). 
Analysing the nearby 291 variants associated with CAD, expression data was available in the GTEx Portal data-
base for 281 of the variants. Interestingly, these linked variants both associate with increased CAD risk and 
decreased NBEAL1 expression in arteries (Fig. 1, Supplemental Table 4). Taken together, we find that linked CAD 
variants in NBEAL1 and nearby genes associate with decreased expression of NBEAL1 in arteries. The causal 
variant remains to be elucidated and whether the genetic associations are explained by the same causal variant. 
However, the analysis suggests that low NBEAL1 expression in arteries confers an increased risk of CAD.
Figure 1. Genetic variants in NBEAL1 are associated with increased risk of coronary artery disease and decreased 
NBEAL1 expression. Regional association plots of NBEAL1 and nearby genes. The top plot shows associations 
with CAD (CARDIoGRAMplusC4D data) and the bottom plot shows expression of NBEAL1 in Artery Tibial 
(GTEx data). SNPs are plotted with their analysis P values (as −log10 values) against their genomic position 
(NCBI Build 38). The local LD structure relative to the top CAD association is displayed on the top plot, with the 
different colors representing the strength of the correlation (based on pairwise r2 values from 1000 G EUR).
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Vascular endothelial cells form an inner lining of the blood vessels and regulate exchanges between the blood-
stream and the surrounding tissues. Endothelial dysfunction is implicated in atherosclerosis and several inter-
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Figure 2. NBEAL1 modulates expression of LDL receptor and LDL uptake. (a) HUVEC cells depleted of 
NBEAL1 using two different siRNAs were sterol-depleted for 2 h using 0.5% MCD or depleted and, where 
indicated, restimulated with cholesterol for 6 h followed by western blotting with indicated antibodies. Asterisk 
denotes unspecific band (N = 3). (b) Quantification of LDLR relative to Actin in HUVEC cells treated as in 
(a) from three independent experiments. All bars show mean ± S.E.M. ****P < 0.0001 by two-way ANOVA 
followed by Tukey’s multiple comparison test. (c) Gene expression of NBEAL1 from (a) presented as mean ± 
S.E.M. Statistical differences were analyzed using one-way ANOVA followed by Dunnett’s multiple comparison 
test relative to siScr. **P < 0.001, ****P < 0.0001 (N = 3). (d) Representative images of 10 min BODIPY-LDL 
uptake in HUVECs with and without depletion of NBEAL1 using two different siRNAs. Cells were grown in 
lipid starved medium for 18 h prior to BODIPY-LDL-uptake. Nuclei are stained with DAPI (blue). Scale bars, 
40 µM (N = 3). (e) Quantification of BODIPY-LDL uptake in NBEAL1 depleted HUVEC cells (e), displayed 
as average intensity per cell (upper panel) and average number of dots (lower panel). Data show mean ± 
S.E.M. relative to control from three independent experiments. On average 500 cells from each condition was 
quantified per experiment using CellProfiler. *P < 0.05, **P < 0.01 by Student’s t-test relative to control. (f) 
Gene expression of NBEAL1 from (d) presented as mean ± S.E.M. Statistical differences were analyzed using 
one-way ANOVA followed by Dunnett’s multiple comparison test relative to siScr. *P < 0.05, **P < 0.01 (N = 3).
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Figure 3. NBEAL1 is a Golgi-associated protein that is degraded by the proteasome. (a) Schematic 
representation of full-length human NBEAL1. Key domains of the protein are highlighted with boxes including 
the Concanavalin A (ConA)-like lectin, the pleckstrin homology (PH), BEACH, and WD40 repeat domains. 
The numbers refer to amino acids. Seven predicted WD40 domains following the NBEAL1 BEACH domain 
by using the RaptorX 3D model prediction program33. These formed a predicted circularized β-propeller 
structure. (b) EGFP-NBEAL1 expressing U2OS cells were treated or not with Brefeldin A for 10 min (5 µg/mL 
final), fixed and subjected to immunofluorescence staining of endogenous Giantin. Scale bars, 10 µm (N = 3). 
(c) Postnuclear supernatant (PNS) and nuclear (NE) fractions from EGFP-NBEAL1 expressing HEK-293T 
cells were immunoblotted with a GFP antibody using Lamin A or α-Tubulin as loading controls (N = 3). (d) 
Cytosolic (Cyt) or membrane (Mem) fractions from EGFP-NBEAL1 expressing U2OS cells were treated or not 
with proteinase K and Triton- X 100 as indicated. Membranes were immunoblotted with a GFP antibody using 
Calnexin or α-Tubulin as cellular fraction controls (N = 3), and Calnexin as a control that was protected upon 
proteinase K treatment alone, but not in combination with 1% Triton X-100. (e) EGFP-NBEAL1 expressing 
HEK-293T cells were treated with or without doxycycline (dox) for 24 h and then chased in complete media 
without doxycycline for the indicated time points (N = 3). (f) Quantified EGFP-NBEAL1 to Actin from three 
independent experiments. All bars show mean ±S.E.M. *P < 0.05, ***P < 0.0001 by one-way ANOVA followed 
by Dunnett’s multiple comparison relative to 0 h. (g) EGFP-NBEAL1 expressing HEK- 293T cells were treated 
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outcomes22. To better understand the link between decreased expression of NBEAL1 in arteries and increased 
risk of CAD we tested if depletion of NBEAL1 in primary endothelial cells (human umbilical vein endothelial 
cells; HUVECs) would modulate expression of adhesion molecules or cholesterol metabolism in these cells. The 
expression of vascular adhesion molecule 1 (VCAM-1) and E-selectin is increased in vascular endothelial cells 
following inflammation, leading to monocyte recruitment23, a hallmark of early stages of artheriosclerosis24,25, 
but are also expressed in early artheriosclerotic lesions26,27 and play a key role in the pathology of artheriosclerosis 
and cardiovascular disease28–30. The expression of both VCAM-1 and E-selectin was robustly increased follow-
ing treatment with the proinflammatory cytokine interleukin-1β (IL-1β), but there were no differences between 
control cells and cells depleted of NBEAL1 (Supplemental Fig. 3a–c). Depletion of RELA (also known as nuclear 
factor NF-kappa-B p65 subunit) was used as a positive control as VCAM-1 and E- selectin are well characterized 
NF-kappa-B target genes. Thus, NBEAL1 does not seem to be important for recruiting monocytes to the endothe-
lial cells in the arteries during inflammatory conditions.
Elevated plasma levels of LDL cholesterol are associated with increased risk of CAD31. LDLR mediates cellular 
LDL uptake and low levels or loss-of-function mutations in LDLR leads to increased plasma LDL and subsequent 
premature CAD31. Because low expression of NBEAL1 was associated with increased risk of CAD, we tested if 
depletion of NBEAL1 could modulate LDLR levels. Interestingly, the expression of LDLR was lower in primary 
endothelial HUVECs depleted of NBEAL1 (using two different siRNA oligos) as compared to control cells starved 
of cholesterol with methyl-β cyclodextrin (MCD), while no significant difference was observed in untreated con-
trol cells or upon cholesterol replenishment following cholesterol starvation (Fig. 2a–c). In line with this, LDL 
uptake was inhibited in serum starved HUVECs depleted of NBEAL1 as compared to control cells (Fig. 2d–f).
No commercial antibodies exist for NBEAL1 and despite several attempts (Supplemental Fig. 4a) we failed to 
generate specific NBEAL1 antibodies. To identify the cellular localization and function of NBEAL1 we therefore 
cloned full length NBEAL1 from U2OS cell cDNA and generated cell lines (T-Rex-Flp-In doxycycline-inducible 
U2OS, HEK-293T and HeLa cells) with stable inducible expression of EGFP-NBEAL1. NBEAL1 has the same 
modular structure as most of the other BEACH proteins with a C-terminal pleckstrin homology (PH), BEACH 
and WD40 repeat domain assembly, and contains an additional Concanavalin A (ConA)-like lectin domain 
(Fig. 3a). The cloned sequence was identical to NM_001114132.1 (9058 base pairs), but lacked base pair 639–848 
corresponding to exon 5–6 (amino acids 10–172) in the predicted sequence, still preserving the predicted mod-
ular structure. We identified this isoform, and several other alternatively spliced isoforms of NBEAL1 by cloning 
and sequencing the 5′ end of NBEAL1 form U2OS cells cDNA (Supplemental Fig. 4b). We also observed several 
NBEAL1 isoforms in the other cell lines used in this study (HeLa, HEK-293T, HUVECs), indicating the presence 
of multiple transcripts of NBEAL1. The functional significance of the different isoforms remains to be elucidated.
The modular structure of NBEAL1 does not provide many functional clues because the ConA, PH and WD40 
domains are found in a wide range of proteins implicated in different cellular pathways and the function of the 
BEACH domain remains unknown. Of the nine BEACH proteins, NBEAL1 is most closely related to NBEAL26, 
but there is no evidence suggesting that they have similar functions. U2OS cells are well suited for imaging and 
stably expressed EGFP-NBEAL1 displayed partly diffuse cytoplasmic staining in addition to localization to the 
Golgi compartment, as visualized by co-localization with the Golgi marker Giantin and a more diffuse staining 
following Brefeldin A treatment to disrupt Golgi (Fig. 3b). A similar localization was seen in cells transiently 
overexpressing 3xFLAG-NBEAL1 or mCherry-NBEAL1 (Supplemental Fig. 5), suggesting that EGFP-NBEAL1 
is either tethered to or localized within the Golgi. EGFP-NBEAL1 was detected as a single band above 250 kDa in 
the post nuclear supernatant fraction (Fig. 3c) and was present both in the cytosol and membrane fraction of 
U2OS cells (Fig. 3d). NBEAL1 was not protected from proteinase K (Fig. 3d), indicating it is associated to and 
not localized within the Golgi compartment. To study the half-life of EGFP-NBEAL1 in HEK-293T cells, protein 
expression was induced by doxycycline and followed over 72 h after removal of doxycycline (Fig. 3e). More than 
70% of EGFP-NBEAL1 was degraded after 24 h (Fig. 3e,f), which was prevented by inhibitors of proteasomal 
(MG-132), but not autophagic (Bafilomycin A1 (BafA1) and chloroquine (CQ)) degradation (Fig. 3g), indicating 
that the proteasome is important for NBEAL1 degradation. LC3 was used as a positive control for inhibition of 
autophagy through BafA1 and CQ-treatment. During autophagy, a cytosolic version of LC3 (LC3-I) is conjugated 
to phosphatidylethanolamine in the autophagosomal membranes (LC3-II) and accumulates upon inhibition of 
lysosomal degradation (Fig. 3g).
Given the inhibitory effect of NBEAL1 knockdown on LDLR expression and LDL uptake (Fig. 2), we asked 
whether overexpression of NBEAL1 in HEK-293T cells, which respond well to cholesterol depletion, would have 
an opposite effect. Indeed, LDLR levels were higher in HEK-293T expressing EGFP-NBEAL1 as compared to 
control cells upon cholesterol starvation (Fig. 3h,i). Uptake of cholesterol through the LDLR is tightly regu-
lated and integrated with de novo synthesis at the transcriptional levels by the sterol regulatory element-binding 
protein 2 (SREBP2) transcription factor and its interacting proteins; sterol regulatory element-binding protein 
cleavage-activating protein (SCAP), insulin-induced gene (Insig) and the recently described progestin and 
or not with dox for 24 h, then chased in complete media in the presence or absence of 100 nM MG-132, 100 nM 
Bafilomycin A1 (Baf) or 50 µM chloroquine (CQ) for 24 h without dox (N = 2). Cell lysates were immunoblotted 
with the indicated antibodies. LC3-II is mainly degraded through autophagy and was used as a control for 
BafA1 and CQ treatment. (h) EGFP-NBEAL1 HEK-293T cells were sterol-depleted for 2 h using 0.5% MCD or 
depleted and, where indicated, restimulated with cholesterol for 6 h following western blotting with indicated 
antibodies (N = 3). (i) Quantification of LDLR relative to GAPDH in HEK-293T expressing EGFP-NBEAL1 
cells treated as in (c) from three independent experiments. All bars show mean ± S.E.M. **P < 0.01 by two-way 
ANOVA followed by Tukey’s multiple comparison test.
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Figure 4. NBEAL1 modulates SREBP2 activity and processing. (a) EGFP-NBEAL1, MYC-SCAP and/
or Cherry-PAQR3 were transiently transfected into U2OS cells followed by immunofluorescence staining 
with MYC antibody. Scale bars, 10 µm (N = 3). (b) HEK-293T cells expressing EGFP or EGFP-NBEAL1 
were transiently transfected with MYC-SCAP. Cells were grown in complete medium (control) or sterol-
depleted for 2 h using 0.5% MCD followed by 2 h restimulation with cholesterol or not. Cell lysates were 
immunoprecipitated with anti-GFP beads, followed by western blotting with the indicated antibodies. (N = 3). 
(c) HEK-293T cells expressing EGFP or EGFP-NBEAL1 were transiently transfected with MYC-PAQR3. Cells 
were grown in complete medium (control) or sterol- depleted for 2 h (MCD), followed by 2 h restimulation 
with cholesterol or not. Cell lysates were immunoprecipitated with anti-GFP beads. (d,e) Interactions between 
co- immunoprecipitated (d) EGFP-NBEAL1 and MYC-SCAP or (e) EGFP-NBEAL1 and MYC- PAQR3 were 
related to MYC input and presented as relative to control (N = 3). Bars represent mean ±S.E.M. *P < 0.05. NS, 
not significant by Student’s t-test. (f) Expression levels measured by qPCR in primary HUVECs depleted of 
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adipoQ receptor family memeber 3 (PAQR3)32,33. When cellular levels of cholesterol are high, SREBP2 is retained 
in the ER bound in a complex with SCAP and Insig. When cellular cholesterol levels drop, SCAP-SREBP2 
dissociates from Insig and trafficks to the Golgi, where the two proteases site-1 protease (S1P) and site-2 pro-
tease (S2P) promote SREBP2 processing, leading to translocation of the mature form of SREBP2 to the nucleus 
where it induces the expression of genes involved in cholesterol uptake and synthesis, including LDLR, 
hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and HMGC synthase (HMGCS). Accordingly, more choles-
terol is produced and feeds back to keep the Insig:SCAP:SREBP2 complex in the ER. PAQR3 is a Golgi-anchored 
transmembrane protein that was found to retain SCAP:SREBP2 in the Golgi and promote SREBP2 matu-
ration32. As NBEAL1 localizes to the Golgi (Fig. 3b) where SREBP2 processing occurs, we tested if NBEAL1 
could interact with the SREBP2 regulatory proteins, PAQR3 and SCAP. EGFP-NBEAL1 partly co-localized with 
MYC-SCAP and Cherry-PAQR3 in the Golgi (Fig. 4a) and interacted with both MYC-SCAP and MYC-PAQR3 
in co-immnoprecipitation assays (Fig. 4b–e). Most interestingly, the interaction between EGFP-NBEAL1 and 
MYC-SCAP increased in HEK-293T cells subjected to cholesterol starvation and was reversed upon cholesterol 
replenishment, with no effect on their expression levels, implying that this interaction is regulated by choles-
terol (Fig. 4b,d). In contrast, neither the Golgi localization nor the interaction between EGFP-NBEAL1 and 
MYC-PAQR3 were affected by cholesterol levels (Fig. 4c,e), suggesting that these proteins form a stable complex. 
Unlike PAQR3, NBEAL1 does not contain any transmembrane domain. The domain(s) of NBEAL1 needed for 
its Golgi-association or the interaction with PAQR3 is not known. PAQR3 was recently reported to modulate 
ER-to-Golgi transport of COPII vesicles by interacting with the WD domains of Sec13 and Sec13A34. To test if the 
WD domain of NBEAL1 interacted with PAQR3, we performed co-IP experiments with MYC-PAQR3 and the 
following EGFP-NBEAL1 domain modular constructs; PH-BEACH-WD40, BEACH-WD40 or only the BEACH 
domain. Full length EGFP-NBEAL1 was used as a positive control and interacted with MYC-PAQR3 as expected. 
Interestingly, all NBEAL1 domain modular proteins interacted with MYC-PAQR3, indicating that the interaction 
between PAQR3 and NBEAL1 is dependent on the BEACH domain of NBEAL1 rather than the WD40 domain 
(Supplemental Fig. 6). This suggests that NBEAL1 does not compete with Sec13 and Sec13A for the interaction 
with PAQR3.
Because NBEAL1 interacted with SREBP2 regulatory proteins, we next asked if NBEAL1 could modu-
late the transcriptional activity of SREBP2. Indeed, depletion of NBEAL1 by two different siRNA oligos in 
cholesterol starved primary endothelial HUVECs reduced the gene expression levels of LDLR, HMGCR and 
HMGCS, but had no effect on expression of genes involved in SREBP2 maturation, including SCAP and PAQR3 
(Fig. 4f). Conversely, elevated expression of SREBP2 target genes was seen in cholesterol-starved HEK-293T 
EGFP-NBEAL1 expressing cells (Fig. 4g). We further examined the effect of NBEAL1 on SREBP activation using 
luciferase reporter constructs driven by Ldlr- and Hmgcr-promoters. These promoters contained binding sites for 
SREBP, so-called sterol regulatory binding elements (SREs), and are mainly regulated by SREBP2. Interestingly, 
overexpression of NBEAL1 elevated the SRE activity on these promoters, supporting that NBEAL1 induces 
SREBP2 activity (Fig. 4h). Further supporting a role for NBEAL1 in regulation of SREBP activation, we found that 
NBEAL1 also had an effect on activation of SREBP1 (Supplemental Fig. 7a–c), which induce the transcription of 
genes involved in fatty acid synthesis and is regulated by SCAP and PAQR32.
To examine whether NBEAL1 could interfere with SREBP2 processing we used a PLAP-BP2 assay35. 
CMV-PLAP-BP2 encodes placental alkaline phosphatase (PLAP) and the regulatory domain of SREBP2 (amino 
acid 513–1141, BP2) that is processed in a way mimicking endogenous SREBP2 processing, resulting in release 
of PLAP to the media, which can be measured by luminescence (Fig. 4i). Interestingly, the PLAP level (indicating 
SREBP2 processing) was significantly higher in HEK-293T EGFP-NBEAL1 cells than in control cells and could 
be reduced by co-depletion of NBEAL1 (Fig. 4j, Supplemental Fig. 7d), indicating that NBEAL1 affects SREBP2 
activity by modulating SREBP2 processing.
Conclusion
NBEAL1 is a poorly understood protein with no reports on its cellular function or physiological relevance. The 
characterization of NBEAL1 knockout mice will be important to understand the physiological role of NBEAL1. 
Herein, we identify human genetic variants in NBEAL1 associated with reduced NBEAL1 expression in arteries 
and increased risk of CAD. We show that NBEAL1 is a Golgi-associated protein that affects cellular cholesterol 
metabolism and LDL uptake by modulating SREBP2 activity and processing in primary endothelial cells and 
HEK-293T expressing NBEAL1 cells. Low expression of NBEAL1 may therefore affect LDL uptake and accord-
ingly LDL levels, which is a risk factor of CAD. Deregulated cholesterol homeostasis promotes the pathology of 
atherosclerosis, myocardial infarction and strokes. Thus, characterization of NBEAL1 as a novel player involved 
in regulation of cholesterol homeostasis may provide early diagnosis of persons at risk or pave the way for ther-
apeutic treatment.
NBEAL1 using two different siRNAs or (g) EGFP- NBEAL1 HEK-293T cells treated or not with doxycycline. All 
cells were starved for cholesterol prior to harvest (N = 3). All bars show mean ± S.E.M. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 by Student’s t-test; NS, not significant. (h) HEK-293T expressing EGFP-NBEAL1 
cells were transfected with Ldlr- or Hmgcr-driven luciferase reporters containing SREs. The Renilla luciferase 
reporter pRL-CMV was used as internal control. Dual luciferase reporter assays were performed 24 hours post 
transfection. Data are presented as mean ± SEM (n = 3). Differences are shown as ***p < 0.001 by Student’s 
t-test. (i) Schematic overview of the SREBP2 processing assay (PLAP, placental alkaline phosphatase). (j) 
SREBP2 processing assay in EGFP-NBEAL1 expressing HEK-293T cells with or without depletion of NBEAL1 
by siRNA. PLAP was measured in media and related to Renilla values (N = 3). Relative levels of PLAP are 
shown ± S.E.M. *P < 0.05, ****P < 0.0001 by Student’s t-test.
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Materials and Methods
Materials. The following antibodies were used: GFP (Clontech #632381 western blot (WB), 1:3,000), MYC 
(WB, Abcam # ab9132, 1:5,000), FLAG (WB, Sigma # F1804, 1:500), Lamin A (WB, Sigma-Aldrich # L1293 
1:1,000), α-Tubulin (WB, Sigma-Aldrich # T5168, 1:20,000), β-Actin (WB, Cell Signaling Technology # 3700, 
1:10,000), GAPDH (WB, Cell Signaling Technology # 5174, 1:5000), NFκB p65 (WB, Santa Cruz Biotechnology 
# sc-372, 1:1000), VCAM-1 (WB, R&D # BBA19, 1:1000), E-selectin (WB, Santa Cruz Biotechnology # sc-14011, 
1:1000), LDLR (WB, BioVision/AH # 3839-100, 1:2,000), Giantin (immunofluorescence (IF), Covance # PRB-
114C, 1:500). Fluorophore-conjugated secondary antibodies were from Thermo Fisher Scientific (IRDye® 
800CW Donkey anti-Rabbit # SA5-10044, IRDye® 800CW Donkey anti-Mouse SA5- 10170) and LI-COR 
(IRDye® 800CW Donkey anti-Goat # 926-32214, IRDye® 680RD Goat anti-Rabbit # 926-68071 D). All sec-
ondary antibodies were diluted 1:10,000. The following experimental materials were used: FBS (Sigma-Aldrich), 
penicillin-streptomycin (Termo Fisher Scientific), doxycycline (Clonetech), blasticidin (Termo Fisher Scientific), 
brefeldin A (Sigma- Aldrich) hygromycin B gold (Sigma-Aldrich), Methyl-beta-cyclodextrin (Sigma-Aldrich), 
cholesterol (Sigma-Aldrich), IL-1β (R&D # 201-LB- 025), Dual Luciferase® reporter assay system (E1960) was 
purchased from Promega (Madison, WI, USA).
Plasmids and transfection for ectopic expression. NBEAL1 was cloned using cDNA library made by 
reverse transcription (Biorad iScript) from mRNA isolated from U2OS cells. Full-length NBEAL1 was ampli-
fied in four regions that were assembled and inserted into pENTR1A (Gateway, Invitrogen) using the Geneart 
Seamless Plus Cloning and Assembly kit (Thermo Fisher Scientific, # A14603). The cloned full-length sequence 
was identical to NM_001114132.1 (9058 base pairs), but lacked base pair 639–848, corresponding to exon 5–6 
(amino acids 10–172) in the predicted sequence. NBEAL1 variants with alternatively spliced N-terminal region 
were identified by PCR of the region between nucleotides 48–1296 or 52–1489 (of NM 001114132.1) from cDNA 
of U2OS cells, which were cloned with Zero Blunt TOPO PCR Cloning Kit (ThermoFisher Scientific), followed 
by sequencing of the obtained constructs. Tagged NBEAL1 constructs were generated by Gateway LR cloning 
(Invitrogen) into respective pDEST vectors (Invitrogen). The pRL-CMV vector was from Promega and the 
pCMV-PLAP-BP2 was a kind gift from Prof. Andrew Brown34. MYC-tagged human PAQR3 and MYC-tagged 
human SCAP was kindly provided from Prof. Yan Chen30. Luciferase reporter plasmids containing SREs were 
kindly provided by Prof. Hitoshi Shimano36. The truncated NBEAL1 constructs; EGFP-PH-BEACH-WD40 (aa 
1815–2694), EGFP-BEACH-WD40 (1969–2694), and EGFP-BEACH (aa 1991–2284) were generated by PCR 
amplification from full length EGFP-NBEAL1. The mCherry-PAQR3 plasmid was created by PCR amplifica-
tion from the cDNA of interest using primers containing KpnI and NotI restriction sites. All plasmids were 
sequenced to ensure correct reading frame (GATC Biotech). Details on the construction of plasmids are available 
upon request. Cells were transfected with plasmids encoding EGFP-NBEAL1 variants using FuGene (Roche) or 
Lipofectamine 2000 (Invitrogen) before further treatment as described.
Cell culture. Human embryonic kidney (HEK)-293T and U2OS cells were from American Type Culture 
Collection and were maintained in Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal 
bovine serum (FBS), 5 U ml−1 penicillin and 50 μg ml−1 streptomycin. FlpIn T- Rex™ HEK-293T and FlpIn 
T-Rex™ U2OS cells with stable inducible expression of EGFP- NBEAL1 were induced with 10–500 ng/mL doxy-
cycline for 24 h before harvest.
Primary human endothelial cells (HUVEC) were isolated as described from infant umbilical vein of deliv-
ering mothers at Rikshospitalet University Hospital35. None of the mothers providing umbilical cords had any 
pregnancy complications. Written informed consent was obtained from each donor and ethical approval for the 
use of HUVEC was obtained from the Norwegian National Research Ethics Committee for medical and health 
research (REK 2013/2123). All methods were performed in accordance with the relevant guidelines and regula-
tions. The cells were established at 37 °C and 5.0% CO2 in MCDB 131 medium (Sigma) containing 5 mM glucose 
and supplemented with 7% heat inactivated fetal calf serum (FCS, Sigma), basic fibroblast growth factor (1 ng/
mL, R&D), epidermal growth factor (10 ng/mL, R&D), hydrocortisone (1 µg/mL, Sigma), gentamicin (50 µg/
mL, GIBCO Invitrogen) and fungizone (250 ng/mL, GIBCO Invitrogen). Cells were used for experiments within 
three passages, and culture medium was changed every 48–72 h. The purity of the endothelial cell cultures was 
verified by microscopic observations of each culture as well as regular staining for the endothelial cell marker von 
Willebrand factor (vWF). For siRNA experiments, the cells were seeded at 1.5 × 105 cells per well in a six well dish 
for three days knockdown with reverse transfection. A pool of minimum four individual donors was used in each 
replicate. Mycoplasma testing was done in the core facility of The Norwegian Center for Stem Cell Research and 
all cell lines were negative for mycoplasma.
RNA isolation and qPCR. RNA was isolated from cells using the RNeasy plus kit (Qiagen). For cDNA 
synthesis, 500 ng of extracted RNA was reverse transcribed using SuperScript III (Invitrogen) and ran-
dom hexamer primers. qPCR was performed with 1 μl of the cDNA synthesis reaction using Kapa SYBR 
FAST qPCR Master Mix (KapaBiosystems). Primers used to amplify genes of interest were; NBEAL1 
(5′-TGCGACTGCCTATCCATTGT-3′, 5′-GACCTGAACGCATCTCAGCA-3′), LDLR (5′-AGTGTGACC 
GGGAATATGACT-3′, 5′-CCGCTGTGACACTTGAACTT-3′), HMGCR (5′-GTTAACTGGAGCCAGG 
CTGA-3′, 5′-CCTTGGATCCTCCAGATCTCAC-3′), HMGCS (5′-TGTCCTTTCGTGGCTCACTC-3′, 5′-GGT 
GAAAGAGCTGTGTGAAGG-3′), PAQR3 (5′-AGCGGTACTTTCCAGGACAAC-3′, 5′-ACTGTTG 
ACTGATGCCACCAA-3 ′),  SCAP (5 ′-ACCTGTGGAATTCACCACCC-3 ′ ,  5 ′-ACCCACATACC 
ACTCAGGCT-3′), FAS (5′-CTTCAAGGAGCAAGGCGTGA-3′, 5′-ACTGGTACAACGAGCGGATG-3′), 
ACACA (5′-GCCTCTCAGAGACAACGTGA-3′ , 5′-GAGAATCTGACCAGCTGAGAGG-3′), ACL 
(5′-GACTTCGGCAGAGGTAGAGC-3′, 5′-AGGAGTTCTTTGCCCGTCTG-3′), ELOVL6 (5′-CAAAGC 
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ACCCGAACTAGGAGA-3′ , 5′-GGAGCACAGTGATGTGGTGA-3′), SCD1 (5′-ACACCCAGCTG 
TCAAAGAGA-3′, 5′-GCCAGGTTTGTAGTACCTCCTC-3′), TBP (5′-TTGTACCGCAGCTGCAAAAT-
3′,5′-TATATTCGGCGTTTCGGGCA-3′). All target transcripts were normalized to Tata-binding protein (TBP) 
and analysed using the comparative CT(ΔΔCT) method. RNA data are presented as mean and S.E.M. for three 
independent experiments.
siRNA experiments. The following siRNA oligonucleotides were used: Dharmacon ON-TARGET Plus; 
NBEAL1- J-031856-18 GGAUAUAACAGCUAGAGUA, NBEAL1-J-031856-20 UCAAACAUGUGGACCGAGA 
and On-Target plus Control siRNA D-001810-01-50; and Thermo Fisher Silencer® Select RELA (# s11914). 
5–25 nM of siRNA was delivered to the cells by reverse transfection using Lipofectamine 2000 RNAi max 
(Invitrogen). Cells were harvested 72 h post transfection for downstream assays and knockdown efficiency was 
validated by qPCR or immunoblotting.
Cell lysis and immunoprecipitation. Whole-cell extracts were prepared in precipitation assay buffer 
(50 mM Tris/HCl pH 7.4, 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM 
EDTA) supplemented with protease inhibitor cocktail (Roche). Nuclear and post-nuclear supernatant fractions 
were prepared using the NE-PER extraction kit (Pierce Biotechnology). Protein concentration was measured by 
Biorad Protein Assay to run equal amounts of cell lysate on SDS–polyacrylamide gel electrophoresis (PAGE), 
followed by western blotting using indicated primary antibodies and fluorophore-conjugated secondary antibod-
ies. Detection and analysis was performed by LI-COR Odyssey imaging. For immunoprecipitation from lysates, 
EGFP, EGFP-NBEAL1, MYC, MYC PAQR3 were immunoprecipitated by GFP (Chromotek) following the man-
ufacturer’s protocol. The resulting immunoprecipitates or pulldowns were separated by SDS–PAGE and analysed 
by western blotting.
Proteinase K protection assay. HEK-293T EGFP-NBEAL1 cells treated with doxycycline were seeded in 
10 cm dishes and harvested in a HES buffer (15 mM Hepes KOH pH 7.4, 1 mM EDTA, 250 mM Sucrose) without 
protease inhibitor cocktail. Cells were lysed using a cell cracker (Isobiotec), and centrifuged 1000 × g 10 min, 4 °C 
to remove intact cells, mitochondria and nucleus. The supernatant was transferred to ULTRA centrifuge tubes 
and centrifuged at 100.000 ×g 30 min, 4 °C. The supernatant (cytosolic fraction) was saved membrane samples 
were re-suspended in HES buffer, HES buffer with 25 µg/mL proteinase K (Roche), or HES buffer with 25 µg/mL 
proteinase K and 1% Triton X-100. Samples were incubated at room temperature for 20 min. Proteinase K was 
then inactivated by adding protease inhibitor cocktail and sample buffer.
Protein degradation assay. EGFP-NBEAL1 expressing HEK-293T cells were treated with or without 
10 ng/mL doxycycline for 24 h. Cells were washed three times in warm media to remove doxycycline followed by 
a 24 h incubation in the presence or absence of 100 nM MG-132, 100 nM Bafilomycin A1 or 50 µM chloroquine.
Cholesterol starvation/stimulation in cells. The cellular cholesterol levels are tightly regulated at the 
transcriptional level by SREBP2 and downstream target genes. Cholesterol starvation experiments can be used to 
induce the cholesterol synthesis. Treatment of cells with MCD is the most common method to deplete cells from 
cholesterol. MCD has a central cavity that can form a 2:1 complex with free cholesterol 2:137. Thus, the cells are 
depleted of cholesterol and switches on SREBP2 dependent gene programs for cholesterol synthesis (i.e. HMGCR 
and HMGCS) and uptake (i.e. LDLR). When the sterol depleted cells are replenished with medium containing 
excess cholesterol, the cells attempt to restore cellular cholesterol levels within the normal range and switch off 
the cholesterol synthesis pathway. HUVEC and HEK-293T were rinsed twice in serum free media and was incu-
bated with empty DEMEM containing 0.5% MCD for 2 h. Cells were then transferred to DEMEM containing 
0.1% MCD (starved condition) or to DMEM containing 20 μg/ml cholesterol pre-complexed with 0.1% MCD 
(resulting in MCD:cholesterol at 1:1 molar ratio, 50 μM) and incubated for 4 h. MCD:cholesterol complexes were 
prepared by diluting a 20 mg/mL cholesterol stock solution (in EtOH) 1000-fold into a 15-ml falcon tube con-
taining DMEM + 0.1% MCD + 0.5% LDS, resulting in 50 μM final concentration of both cholesterol and MCD.
Indirect Immunofluorescence. Cells were seeded on fibronectin-coated coverslips (10 µg/mL) and trans-
fected with siRNA as described above or with EGFP-NBEAL1 construct 24 h after plating. Cells were, where indi-
cated, treated or not with Brefeldin A for 10 min (5 µg/mL final). Twentyfour hours after transfection, cells were 
washed twice in PBS and fixed with 4% paraformaldehyde on ice. The cells were then permeabilized in a solution 
containing 5% FBS and 0.05% saponin (Sigma - Aldrich) in PBS before incubation with primary antibody for 1 h, 
washed in PBS and incubated with secondary antibodies for 45 min. Cells were washed in PBS and nuclei were 
counterstained with Hoechst (1:1000 dilution of 10 μg/mL stock) in PBS for 10 min. The coverslips were mounted 
with ProLong® Gold Antifade Mountant (Thermo Fisher Scientific). Confocal microscopy was performed using 
Zeiss LSM 710 ELYRA.
Luciferase reporter assay. HEK-293T expressing EGFP-NBEAL1 cells were seeded in 24-well plates at 1 × 
105 cells per well and incubated for 24 h. Cells were transfected with 200 ng of luciferase reporters containing SREs 
(pGL2-LDLR-luc, pGL2-HMGCS-luc, pGL2-FAS-luc). Renilla luciferase reporter (pRL-CMV; 50 ng) was included 
as an internal control for transfection efficiency. All transfections were performed with Lipofectamine 2000. Dual 
luciferase reporter assay was performed 24 hours post transfection as previously described38 After 18 hours of incu-
bation, cells were washed with PBS and lysed in Passive Lysis Buffer (Promega, Madison, WI). Dual-Luciferase® 
Reporter Assays (Promega, #E1960) were run on a Synergy H1 plate reader (BioTek® Instruments, Winooski, 
VT) according to manufacturer’s manual. Readings of Firefly Luciferase were normalized to the Renilla Luciferase 
readings, and data from three independent transfections experiments run in duplicates are presented.
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SREBP2-processing assay. Analysis of SREBP-2 processing was measured by a secreted alkaline phos-
phatase assay as described previously35. In brief, HEK-293T expressing EGFP-NBEAL1 cells were seeded in 
24-well plates at 1.2 × 105 cells per well and incubated for 24 h. Cells were co-transfected with 0.05 µg pRL-CMV 
and 0.45 µg pCMV-PLAP-BP2 using Lipofectamine 2000. The pCMV- PLAP-BP2 contains a fusion protein, 
which codes for placental alkaline phosphatase (PLAP, amino acid 1–506) and the regulatory domain of SREBP2 
(BP2, amino acid 513–1141). The PLAP is flanked by a cleavage sites for a signal peptidase and Site-1 protease 
(S1P) and cleaved by endogenous S1P upon SREBP2 processing. When SREBP2 is processed, the cleavage of 
both proteases leads to PLAP secretion into the media. PLAP was measured by Phospha-Light™ SEAP Reporter 
Gene Assay System according to manufacturer’s recommendation (Thermo Fisher Scientific). The cells were 
immediately lysed in passive lysis buffer (Promega). The transfection level of pRL-CMV was detected using the 
Stop-Glow component from Dual-Luciferase® Reporter Assay System (Promega) according to manufacturer’s 
protocol and used as a control for transfected cells.
LDL uptake. LDL uptake was measured using using fluorescently labelled Low Density Lipoprotein from 
Human Plasma, BODIPY® FL complex (Thermo Fisher Scientific # L3483) according to manufacturer’s protocol. 
In brief, HUVECs were reverse transfected with indicated siRNA oligos and seeded at 1 × 104 on gelatin coated 
chamber slides. Cells were changed to lipid-deprived media containing 2% lipid depleted serum 24 h before har-
vest. Cells were labelled with 15 µg/mL BODIPY® FL for 30 min on ice and chased for 10 min at 37 °C. Cells were 
fixed in 4% paraformaldehyde on ice, washed three times in PBS and counterstained with Hoechst in PBS. The 
intensity was quantified from an average of 500 cells per experiment and each experiment represent cells pooled 
from four individual donors. For quantitative analysis, cells were imaged on a Zeiss Cell Observer microscope. 
The Zen Blue software (Zeiss) was used for automated capture of 40 images per sample with a 20x magnification. 
A pipeline was created in Cellprofiler39,40 to count dots and to measure intensity per cell. KNIME was used for 
data mining and analysis41.
Statistical analysis. All data are presented as means and S.E.M. Two-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison tests, one-way ANOVA followed by Dunnett’s multiple comparison 
test or two-tailed Student’s t tests were used to assess statistical significance (P < 0.05). Statistical tests applied 
are described in the figure legends. The tissue expression data used for the analyses described in this manu-
script were obtained from the GTEx Portal on 11/09/2018. The UCSC Xena browser was utilized for analyzing 
expression data (http://xena.ucsc.edu/), Kallisto was used for analyzing isoform expression42. GWA data from 
the CARDIoGRAMplusC4D consortium was retrieved from T2D-GENES Consortium, GoT2D Consortium, 
DIAGRAM Consortium (Type2Diabetes Knowledge Portal) on 3/20/2017, and minor allele frequency reported 
for Europeans based on data from the 1000 Genomes Project. Linkage disequilibrium (LD) analysis was per-
formed using SNAP43. Variants were visualized using the TOPPAR software44.
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